Massachusetts-based Revvity, Inc. (RVTY) is a global life sciences and diagnostics company that provides instruments, reagents, software, and services to support drug discovery, clinical research, and medical diagnostics. Valued at $9.5 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. Companies worth $10 billion or more are generally described as “large-cap st ...

Core Insights - Thermo Fisher Scientific Inc. is recognized as one of Goldman Sachs' top healthcare stocks, with a strong strategic outlook presented by CEO Marc Casper at the 47th Annual Raymond James Institutional Investor Conference [1]. Group 1: Growth Prospects - The company is positioned to achieve a growth rate of 3% to 4% by 2026, building on a 2% organic growth from the previous year and targeting a long-term expansion rate of 5% to 6% [3]. - Growth will be driven by the integration of AI to enhance operations and capitalize on market opportunities, alongside a focus on mergers and acquisitions to strengthen the core business [3][4]. Group 2: Acquisition Strategy - Thermo Fisher is in the process of completing the acquisition of Olink, which is expected to enhance its endpoint solution capabilities [4]. - The company is also targeting additional acquisitions aimed at delivering high value to customers and generating strong returns [4]. Group 3: Market Position - Thermo Fisher Scientific is a global leader in serving science, providing over 2 million products and services across pharmaceutical development, biotechnology research, clinical diagnostics, and laboratory management [5].

Core Insights - MKS Inc. has received approval for its near-term science-based emissions reduction targets from the Science Based Targets initiative (SBTi) [1][2] Group 1: Emissions Reduction Commitments - The company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2022 as the baseline year [2] - MKS has committed that 69% of its suppliers and customers, in terms of emissions from purchased goods and services and the use of sold products, will have science-based targets by 2030 [2] Group 2: Framework and Accountability - The approved targets provide a framework for accountability and progress in reducing emissions across MKS's value chain [3] - The company has recalculated its Scope 1 and 2 emissions inventory to reflect a broader portion of its operations and expanded its Scope 3 emissions calculations in line with SBTi criteria [3] Group 3: Reporting and Transparency - MKS reports on its progress toward climate goals in its annual Environmental, Social and Governance (ESG) Report [4]

Core Viewpoint - Waters Corporation has reported strong fourth-quarter earnings, surpassing estimates, but the stock has seen a decline of approximately 8.4% since the last earnings report, underperforming the S&P 500 [1] Financial Performance - Waters reported Q4 2025 non-GAAP earnings of $4.53 per share, exceeding the Zacks Consensus Estimate by 0.67% and reflecting a year-over-year increase of 10.5% [2] - Net sales reached $932.4 million, surpassing the Zacks Consensus Estimate by 0.55%, with a reported increase of 7% year-over-year and 6% on a constant currency basis [2] Segment Performance - The Waters segment generated sales of $823.9 million, up 8% on a reported basis and 7% on a constant currency basis year-over-year, while the TA segment reported flat sales of $108.4 million [3] - Instrument sales were $432.9 million, up 3% year-over-year, Services sales were $329.1 million, increasing 9%, and Chemistry sales were $170.3 million, growing 13% [4] Market Performance - The Pharmaceutical market generated sales of $540.6 million, an 8% increase year-over-year, while Industrial sales were $284.5 million, also up 8%. Government & Academic sales decreased by 2% to $107.3 million [5] - Sales by region included $283.9 million from Asia (up 4%), $332.4 million from the Americas (up 4%), and $315.9 million from Europe (up 13% reported) [6] Operating Expenses - Non-GAAP selling and administrative expenses were $191 million, up 13.3% year-over-year, with an adjusted operating margin of 35.2%, contracting 20 basis points [7] Balance Sheet and Cash Flow - As of December 31, 2025, cash and cash equivalents were $587.8 million, up from $459.1 million in September. The company generated cash from operations of $164.5 million and reported free cash flow of $125.2 million [8] Guidance - For Q1 2026, Waters expects sales growth between 7% and 9% on a constant currency basis, with projected sales of $718-$731 million on an organic reported basis [10] - For FY 2026, the company anticipates constant currency sales growth of 5.5% to 7%, with expected non-GAAP earnings in the range of $14.30 to $14.50 per share, reflecting year-over-year growth of approximately 8.9% to 10.4% [11] Estimate Revisions - Since the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting down by 9.42% [12] VGM Scores - Waters has a subpar Growth Score of D and a Momentum Score of C, with an overall aggregate VGM Score of D, indicating it is in the bottom 40% for value investors [13] Industry Comparison - Waters is part of the Zacks Medical - Instruments industry, where competitor Hologic reported revenues of $1.05 billion, reflecting a year-over-year change of +2.5% [15]

Core Viewpoint - Agilent Technologies, Inc. has experienced fluctuating stock performance post-COVID, with its historical growth trajectory disrupted as the life sciences industry stabilized after the pandemic [3]. Group 1: Company Overview - Agilent Technologies provides instruments, software, and services for life sciences, diagnostics, and chemical analysis, including chromatography, spectroscopy, genomics, and laboratory automation solutions [3]. - The company is likened to Danaher in its role as a supplier to the life sciences sector, indicating a strong position within the industry [1]. Group 2: Stock Performance - Prior to the COVID-19 pandemic, Agilent's stock performance was characterized as a "thing of beauty," indicating strong growth and investor confidence [3]. - During the pandemic, Agilent's stock saw significant gains, but post-pandemic, the stock has faced volatility as the demand for new equipment from life sciences companies diminished [3]. Group 3: Market Context - The life sciences industry, including Agilent, has faced challenges as companies have sufficient equipment, leading to a prolonged period of underperformance for the sector [3].

Core Insights - MKS Inc. operates in the technology sector, providing instruments, subsystems, and process control solutions across various industries, including semiconductor and life sciences [1] Insider Activity - Gerald G. Colella, a director at MKS Inc., sold 10,000 shares at approximately $253.97 each, retaining 40,017 shares post-sale [2] - John Edward Williams, Executive Vice President, sold 2,043 shares at an average price of $256.41, resulting in a 35.95% decrease in his ownership, leaving him with 3,640 shares valued at around $933,332 [3] Stock Performance - MKS Inc.'s stock opened at $253.71 with a market capitalization of $17.04 billion and a P/E ratio of 58.06, indicating high investor valuation [4] - The stock has a beta of 1.94, suggesting it is more volatile than the market [4] Financial Health - The company has a debt-to-equity ratio of 1.53, a current ratio of 2.71, and a quick ratio of 1.71, indicating its ability to meet short-term obligations [5] - The fifty-day moving average is $206.74, while the two-hundred-day moving average is $157.93, showing an upward trend over time [5]

Core Insights - Standard BioTools Inc. reported better-than-expected financial performance for the fiscal year 2025, driven by disciplined execution and operational efficiency [3] - The company has fully operationalized over $40 million in cost savings, leading to lower operating expenses and progress towards profitability targets for 2026 [3] - Following the strategic sale of SomaLogic to Illumina, the company has a strong balance sheet with approximately $1 billion in net operating loss (NOL) carryforwards, providing flexibility for future mergers and acquisitions [3][10] Financial Performance - For Q4 2025, revenue from continuing operations was $23.8 million, a decrease of 4% year-over-year, while full-year revenue was $85.3 million, down 6% year-over-year [6][11] - Consumables revenue in Q4 2025 was $9.0 million, down 17% year-over-year, attributed to declines in project funding [7] - Instruments revenue increased by 10% year-over-year to $8.5 million in Q4 2025, reflecting growth in imaging despite capital constraints in end-markets [9] Operating Expenses and Losses - Operating expenses for Q4 2025 were $36.0 million, a decrease of 4% compared to Q4 2024, including $2.1 million in restructuring charges [9] - The net income for Q4 2025 was $13.9 million, a significant improvement from a net loss of $27.2 million in Q4 2024, primarily due to a one-time tax benefit [9] - The full-year net loss for 2025 was $58.8 million, an improvement of 35% compared to a net loss of $90.9 million in 2024 [10] Gross Margins - Gross margins for Q4 2025 were approximately 47.8%, up from 45.8% in Q4 2024, while non-GAAP gross margins were approximately 50.3%, compared to 48.1% in the prior year [9] - For the full year 2025, gross margins were approximately 49.9%, slightly up from 49.3% in 2024, with non-GAAP gross margins at 53.6%, compared to 53.3% in 2024 [10] Future Outlook - The company expects revenue for fiscal year 2026 to be in the range of $80 million to $85 million, with seasonality similar to prior years [11] - The strategic sale of SomaLogic is anticipated to fuel the company's inorganic growth strategy, supported by a cash balance of approximately $550 million post-transaction [6]

Core Viewpoint - MKS Inc. will participate in a fireside chat at Morgan Stanley's Technology, Media & Telecom Conference on March 2, 2026, highlighting its role in enabling technologies that transform various industries [1]. Company Overview - MKS Inc. is a global provider of foundational technology solutions for semiconductor manufacturing, electronics, packaging, and specialty industrial applications [3]. - The company focuses on creating instruments, subsystems, systems, process control solutions, and specialty chemicals technology to enhance process performance and productivity [3]. - MKS's solutions address challenges in miniaturization and complexity in advanced device manufacturing, enabling increased power, speed, feature enhancement, and optimized connectivity [3]. - The company also meets the growing performance requirements across a wide range of specialty industrial applications [3]. Investor Relations - The live webcast of the conference session will be available on the company's Investor Relations website, with a replay accessible for a limited time afterward [2]. - The contact for investor relations is Paretosh Misra, Vice President, who can be reached via telephone or email for further inquiries [4].

Core Viewpoint - MKS Inc. will participate in a fireside chat at Morgan Stanley's Technology, Media & Telecom Conference on March 2, 2026, highlighting its role in enabling technologies that transform various industries [1]. Company Overview - MKS Inc. is a global provider of foundational technology solutions for semiconductor manufacturing, electronics, packaging, and specialty industrial applications [3]. - The company focuses on creating instruments, subsystems, systems, process control solutions, and specialty chemicals technology to enhance process performance and productivity [3]. - MKS's solutions address challenges in miniaturization and complexity in advanced device manufacturing, enabling increased power, speed, feature enhancement, and optimized connectivity [3]. - The company also meets the growing performance requirements across a wide range of specialty industrial applications [3]. Investor Relations - The live webcast of the upcoming fireside chat will be available on the company's Investor Relations website, with a replay accessible for a limited time [2]. - Paretosh Misra serves as the Vice President of Investor Relations, providing contact information for inquiries [4].

Agilent Technologies, Inc. (A) is a leading provider of instruments, software, services and consumables that support laboratory workflows across life sciences, diagnostics and applied chemical markets worldwide. Agilent is headquartered in Santa Clara, California and has a market cap of $35.8 billion, reflecting its significant presence in the healthcare and research tools sector. The healthcare stock has underperformed the broader market over the past year. Agilent’s stock prices have declined 7.9% over ...